Navigation Links
National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
Date:10/25/2007

This development places National Stem Cell in the sector for Anti-aging products and services, presently a $30 Billion Market, and one of the

Biggest Marketing Opportunities in the U.S. Today

MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC Bulletin Board: NHGI - News) today announced that it is currently in final stage negotiations to exclusively license one of its recently discovered biomaterials which holds promise as an effective anti- aging agent and treatment.

This biomaterial appears to promote the skin's natural ability to maintain youthful tone, texture and viscoelasticity. It is one of a group of recently discovered biomaterials, derived from the company's stem cell and progenitor cell lines, that may stimulate a variety of naturally occurring physiological mechanisms that are involved with the skins ability to preserve and repair itself. This group of biomaterials, for which a provisional patent has recently been filed, also holds promise for a broader and more intensive range of applications such as tissue repair for wound care.

Anti-aging is presently a $30 billion market and arguably, one of the biggest market opportunities in the U.S. today. In the next three years, it is expected to grow to $70 billion. There are 75 million Baby Boomers in the U.S. with 53 million between the ages of 40 and 50, according to Government Accounting Office. Every day 11,000 Baby Boomers turn 50 and this trend will continue for the next 10 years.. By 2012, 50 percent of the population will be over age 50; People over 50 years of age control 70 percent of the financial assets in the USA and 50 percent of all discretionary income.

National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. In addition to its work with stem cell therapeutics, the Company is also working to leverage its commercial infrastructure and product development capabilities of its wholly-owned subsidiary The Sperm Bank of NY. The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company is headquartered in Mountainside, NJ. For more information, please visit http://www.nationalstemcell.com.

"Safe Harbor Statement" Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005, the Company's Quarterly Report on Form 10-QSB for the first quarter ended March 31, 2006. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
2. Schneider National exec joins TrafficCast board
3. Olympics of biotechnology has international flavor
4. Wisconsin professors elected to National Academy of Sciences
5. CIO Leadership Series: Judy Lemke, Schneider National
6. National angel investment grew 11 percent in `06
7. National broadband policy: Lets get it right this time
8. National Academies induct five UW researchers
9. Traffic data firm navigates international business
10. National Bio and Agro Defense fits Wisconsin
11. CATI takes tech transfer model national
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):